Week in Review: Suzhou Abogen Raises $700 Million for mRNA COVID Vaccine

COVID-19 Pandemic   Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine; Brii Bio, a Beijing-North Carolina company, said its combination mAb therapy reduced hospitalization and death in early-stage COVID-19 patients by 73%;  Deals and Financing   BeyondSpring, a US-China company, out-licensed China commercialization rights for its lead oncology to Hengrui Pharma in a $200 million agreement; Beijing Kangle Weishi Biotech completed a $157 million pre-IPO financing to develop recombinant vaccines based on its virus-like particle platform; Suzhou Alphamab Oncology out-licensed  China  rights for its anti-HER2 bispecific antibody to CSPC Pharma in a deal worth up to $150 million; Guangzhou Bio-Thera sold US commercialization rights for its Stelara® biosimilar to Hikma Pharma in a $150 million agreement; Lynk Pharmaceuticals completed a Series B financing of $50 million to conduct Phase I/II clinical trials of its small molecule pipeline; Ocumension Therapeutics of  Shanghai  acquired  China  rights for two approved Novartis ophthalmic drugs in a $35 million deal; Suzhou Innovent and  San Francisco 's Bolt Bio will partner to discover three immune-stimulating antibody conjugate candidates for cancer;  Trials and Approvals   Shanghai Everest Medicines has begun a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer; Shanghai Reistone Biopharma reported positive results from a Phase II trial of its JAK1 inhibitor for alopecia areata, an autoimmune disease; LianBio, a Shanghai-Princeton in-licensing company, started a China Phase IIa trial of infigratinib, an FGFR2 inhibitor, for patients with gastric cancers.  Stock Symbols: (HK: 2137) (NSDQ: BYSI) (SHA: 600276) (HK: 9966)  (HK: 1093) (SHA: 688177)  (LSE: HIK) (HK: 1477)  (NYSE: NVS) (HK: 01801) (NSDQ: BOLT) (HK: 1952) Share this with colleagues: // //